There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. After-hours trades for Pacific Biosciences of California Inc. (PACB) shows that investor sentiment remained broken, with the stock’s consolidated last price falling by -$0.47, or -4.34%, to $10.37. The Pacific Biosciences of California Inc. has recorded 110,455 volume in the after hours trading session. Earlier, Yahoo Finance discussed this stock as it revealed Pacific Biosciences of California, Inc. Announces Pricing of Upsized Public Offering of Common Stock.
This NASDAQ-listed company operates within the Diagnostics & Research industry segment, falling under the Healthcare sector. At the end of the last regular session, the stock closed at $10.84 and fluctuated between $11.52 as its day high and $10.69 as its day low. The current market capitalization of Pacific Biosciences of California Inc. is $2.45B. A total of 2.35 million shares were traded on the day, compared to an average of 4.71M shares.
Insider trades can also provide insight into a stock’s future direction. During the recent three months, PACB has seen 0 BUY and 2 SELL insider trades, representing the acquisition of 0 and the disposition of 71,722 shares. Over the last 12 months, there were 8 BUYs and 9 SELLs from insiders. Insiders purchased 927,500 shares during that period but sold 5,034,431.
In the most recent transaction, Van Oene Mark sold 26,722 shares of PACB for 9.53 per share on Jan 10. After the transaction, the insider now owns 640,808 company shares. In a previous transaction on Dec 01, HENRY CHRISTIAN O sold 45,000 shares at 10.84 per share. PACB shares that insider owns now total 643,551.
Among the insiders who sold shares, Kim Susan G. disposed of 12,968 shares on Sep 29 at a per-share price of $5.61. This resulted in the insider holding 163,488 shares of PACB after the transaction. In another insider transaction, HENRY CHRISTIAN O sold 91,307 shares at $5.78 per share on Sep 15. Company shares held by the insider now total 688,551.
Even though price targets are rarely accurate, they do tend to exert some kind of influence from time to time and are often considered important by markets. According to analysts who have offered 12-month price targets for PACB in the last 3 months, the mean price target is $12.14 with high estimates of $14.00 and low estimates of $10.00. In terms of 52-week highs and lows, PACB has a high of $14.20 and a low of $3.85.
As of this writing, PACB has an earnings estimate of -$0.33 per share for the current quarter. EPS was calculated based on a consensus of 6 estimates, with a high estimate of -$0.31 per share and a lower estimate of -$0.36. The company reported an EPS of -$0.37 in the last quarter, which was -19.40% lower than expectations of -$0.31.
Balance Sheet Annually/Quarterly
In a balance sheet, you can see what assets and liabilities the company has, as well as how much equity investors have invested. These figures can be used to calculate a company’s financial ratios to give investors a better idea of its prospects.
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 7 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for PACB is Overweight with a score of 4.14. A total of 3 analysts rated the stock as Buy while 0 rated it as Overweight while 4 rated it as Hold. Among the other participants, 0 thought the stock was Underweight and 0 thought it should be Sold.